Institut für Medizinische Mikrobiologie, Virologie und Hygiene, Universitätsklinikum Hamburg-Eppendorf, Martinistraße 52, D-20246, Hamburg, Germany.
Eur J Clin Microbiol Infect Dis. 2021 May;40(5):979-985. doi: 10.1007/s10096-020-04094-1. Epub 2020 Nov 27.
Increasing worldwide, prevalence of carbapenem-resistant gram-negative bacteria demands urgent a need for rapid detection and accurate identification of carbapenemases. The BD Phoenix CPO detect (PCD) assay possesses an in-built capacity for parallel susceptibility testing and detection of carbapenemases. Here, the ability of the assay to detect and classify carbapenemase production was tested in a collection of carbapenem-resistant Enterobacterales and non-fermentative gram-negative rods. The ability of the PCD assay to detect and classify carbapenemases was investigated in a collection of 194 clinical, carbapenem-resistant isolates (Enterobacterales [n = 65]; non-fermentative gram-negative rods [n = 129]). AST results were compared to MICS determined by gradient diffusion to determine accuracy of the PCD assay. The accuracy of the PCD assay to detect carbapenemases was compared to the results of molecular isolate characterization using a LDT multiplex carbapenemase PCR assay. All 194 isolates classified as carbapenem-resistant by reference susceptibility testing were also classified correctly as CRO by the PCD assay. Performance analysis of the PCD assay to detect carbapenemase production revealed an overall sensitivity of 98.29% and specificity of 17.95% for the detection of carbapenemase production. For the classification of carbapenemases classes A, B, and D, the PCD correctly classified 79.17% Enterobacterales and 67.16% non-fermentative gram-negative rods. The PCD assay is a reliable tool for the detection of carbapenem resistance and allows for parallel analysis of carbapenemase production. However, while sensitivity is high, low specificity in carbapenemase detection and erroneous classification demands mandatory confirmation by alternative methods, especially in non-fermentative gram-negative bacteria.
全球范围内,碳青霉烯类耐药革兰氏阴性菌的流行率不断增加,因此迫切需要快速检测和准确识别碳青霉烯酶。BD Phoenix CPO detect(PCD)检测法具有并行药敏检测和碳青霉烯酶检测的内置能力。在此,我们测试了该检测法在一组碳青霉烯类耐药肠杆菌科和非发酵革兰氏阴性杆菌中检测和分类碳青霉烯酶产生的能力。我们在 194 株临床碳青霉烯类耐药分离株(肠杆菌科 [n = 65];非发酵革兰氏阴性杆菌 [n = 129])中研究了 PCD 检测法检测和分类碳青霉烯酶的能力。AST 结果与梯度扩散法确定的 MIC 值进行比较,以确定 PCD 检测法的准确性。我们将 PCD 检测法检测碳青霉烯酶的准确性与使用 LDT 多重碳青霉烯酶 PCR 检测法对分子分离物特征的结果进行了比较。参考药敏试验将所有 194 株分离株分类为碳青霉烯类耐药,PCD 检测法也正确地将其分类为碳青霉烯类耐药。检测碳青霉烯酶产生的 PCD 检测法的性能分析显示,检测碳青霉烯酶产生的总灵敏度为 98.29%,特异性为 17.95%。对于 A、B 和 D 类碳青霉烯酶的分类,PCD 正确分类了 79.17%的肠杆菌科和 67.16%的非发酵革兰氏阴性杆菌。PCD 检测法是一种可靠的检测碳青霉烯类耐药性的工具,允许并行分析碳青霉烯酶的产生。然而,虽然灵敏度较高,但碳青霉烯酶检测的特异性较低,且分类错误,需要通过替代方法进行强制性确认,尤其是在非发酵革兰氏阴性杆菌中。